Abstract
Introduction
Osteoarthritis (OA) is a slow progressive disease and a huge economic burden. A new target for therapy could be a growth factor treatment to prevent the loss of cartilage following injuries to the joint. BMP-7 is a promising candidate for such a novel therapy based on growth factors. In this study we combined the chondroprotective effects of BMP-7 with a novel thermosensitive hydrogel to prevent cartilage degeneration in a murine OA model.
M&M
A BDI based thermosensitive hydrogel (Pluronic 123 with Butandiisyocyanate (BDI); LivImplant GmbH, Germany) was augmented with BMP-7 (rh-BMP-7, Olympus Biotech, France; 0.2 µg BMP-7/10µg Hydroge). To investigate the effects on OA progression we used the murine DMM (Destabilization of the medial meniscus) model for OA induction. Animal testing was approved by the Government Commitee of Upper Bavaria (file reference: 55.2-1-54-2532-150-13). A total of 38 C57BL/6 mice were included in this study. Immediately after the DMM surgery and wound closure BMP-7 mixed with BDI Hydrogel or only the BDI Hydrogel was administered via intraarticular injection. The following groups were examined: A) BMP-7 augmented BDI hydrogel B) only BDI hydrogel C) no injection following surgery D) control, healthy contralateral knee joint. After 4 (n=4 per group) and 8 (n=8) weeks mice were euthanized and knees were compared histologically.
Results/Discussion
After 4 weeks the BMP-7 treated group showed a significant lower cartilage erosion compared to the group which only received DMM surgery. In the BMP-7 treated knee, osteoarthritis progression was also milder after 8 weeks than in knees of the DMM group. In all knees, except the control group, cartilage degeneration further progressed throughout the observation period. The contralateral joints showed no severe OA. We did not observe any inflammation or systemic reaction to the hydrogel.
Taken together, we can conclude that BMP-7 showed a positive effect on the cartilage structure. Yet, the effect of a single administration is not strong enough to see a significant effect after 8 weeks. Furthermore, we can conclude, that the intraarticular administration of a thermosensitive hydrogel is an easy and feasible way to administer active agents precise to the joint.
